• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by CryoPort Inc.

    8/11/25 9:54:30 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    NT 10-Q 1 cyrx-20250630xnt10q.htm NT 10-Q Form 12b-25

    ​

    ​

    ​

    ​

    UNITED STATES

    ​

    ​

    SECURITIES AND EXCHANGE COMMISSION

    ​

    ​

    Washington, D.C. 20549

    ​

    ​

    FORM 12b-25

    SEC FILE NUMBER

    001-34632

    NOTIFICATION OF LATE FILING

    CUSIP NUMBER

    229050307

    ​

    ​

    ​

    ​

    ​

    ​

    (Check one):

    ◻  Form 10-K

    ◻  Form 20-F

    ◻  Form 11-K

    ​

    ​

    ⌧  Form 10-Q

    ◻  Form 10-D

    ◻  Form N-CEN

    ◻  Form N-CSR

    ​

    For Period Ended: June 30, 2025

    ​

    ◻    Transition Report on Form 10-K

    ◻    Transition Report on Form 20-F

    ◻    Transition Report on Form 11-K

    ◻    Transition Report on Form 10-Q

    For the Transition Period Ended:                                                                        

    ​

    ​

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

    ​

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

    ​

    PART I — REGISTRANT INFORMATION

    ​

    CRYOPORT, INC.

    Full Name of Registrant

    ​

    ​

    Former Name if Applicable

    ​

    112 Westwood Place, Suite 350

    Address of Principal Executive Office (Street and Number)

    ​

    Brentwood, TN 37027

    City, State and Zip Code

    ​

    ​

    ​

    ​

    SEC 1344 (01-19)

    Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

    ​

    ​


    ​

    ​

    ​

    Board of Governors of the Federal Reserve System

    OMB Number 7100-0091

    Approval expires February 28, 2026

    ​

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

    ​

    ⌧

    (a)
    The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    ​

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    The Registrant is unable to file the subject report in a timely manner because the Registrant was not able to timely compile the subject report without unreasonable effort or expense. The Registrant fully expects to be able to file within the additional time allowed by this report.

    PART IV — OTHER INFORMATION

    (1)

    Name and telephone number of person to contact in regard to this notification

    ​

    ​

    ​

    ​

    ​

    ​

    Robert S Stefanovich

        

    949

        

    681-2727

    (Name)

    ​

    (Area Code)

    ​

    (Telephone Number)

    ​

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).       ⌧ Yes       ☐ No

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?       ⌧ Yes        ☐ No

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

    On August 5, 2025, the Registrant issued a press release announcing financial results for the quarter ended June 30, 2025, and included a copy of such press release as an exhibit to the Registrant’s Current Report on Form 8-K furnished by the Registrant with the Securities and Exchange Commission on August 6, 2025. Information about the Registrant’s financial results for the quarter ended June 30, 2025 compared to the three months ended June 30, 2024 was included in such press release.

    ​

    ​


    ​

    ​

    ​

    ​

    CRYOPORT, INC.

    ​

    ​

    (Name of Registrant as Specified in Charter)

    ​

    ​

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    Date

    August 12, 2025

        

    By

    /s/ Robert S Stefanovich

    Robert S Stefanovich

    Chief Executive Officer

    ​


    Get the next $CYRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    8/6/2025$16.00Market Perform → Outperform
    Leerink Partners
    7/22/2025$13.00Overweight
    Stephens
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cryoport Reports Second Quarter 2025 Financial Results

    Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir

    8/5/25 4:19:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025

    NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. E

    7/22/25 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers

    New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn., July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures.

    7/8/25 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    8/14/25 4:32:02 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    8/13/25 5:16:46 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CryoPort Inc.

    10-Q - Cryoport, Inc. (0001124524) (Filer)

    8/11/25 9:57:47 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Stefanovich Robert sold $80,618 worth of shares (9,300 units at $8.67) and exercised 26,164 shares at a strike of $3.07, increasing direct ownership by 9% to 207,213 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/21/25 5:00:11 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO Shelton Jerrell exercised 25,000 shares at a strike of $5.00, increasing direct ownership by 2% to 1,062,419 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/15/25 5:00:15 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO Shelton Jerrell exercised 25,000 shares at a strike of $5.00, increasing direct ownership by 2% to 1,037,419 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/4/25 6:00:17 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Financials

    Live finance-specific insights

    View All

    Cryoport Reports Second Quarter 2025 Financial Results

    Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir

    8/5/25 4:19:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025

    NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. E

    7/22/25 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports First Quarter 2025 Financial Results

    Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

    5/7/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 1:34:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/13/24 7:16:51 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

    Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

    1/14/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Announces Appointment of Linda Baddour to its Board of Directors

    NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

    3/3/21 4:08:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Appoints Martin Schmieg to Board of Directors

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

    12/1/20 6:30:00 AM ET
    $BCTX
    $CLBS
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cryoport upgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight

    8/6/25 7:50:22 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00

    8/6/25 7:21:40 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens resumed coverage on Cryoport with a new price target

    Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00

    7/22/25 7:52:13 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care